drugset / Trial / NCT06214481

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

NCT06214481

Phase 1 Completed 20 enrolled Amgen
NaSingle-groupOpen-labelBasic science

Summary

The primary objective of the study is to evaluate the pharmacokinetics of rocatinlimab after single subcutaneous (SC) administration in healthy Chinese participants.

Timeline

Start
2024-01-23
Primary completion
2024-05-27
Completion
2024-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rocatinlimab Monoclonal antibody Subcutaneous

Indications